|
1
|
He J, Gu D, Wu X, Reynolds K, Duan X, Yao
C, Wang J, Chen CS, Chen J, Wildman RP, et al: Major causes of
death among men and women in China. N Engl J Med. 353:1124–1134.
2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Abbas MT, Baba Ali N, Farina JM, Mahmoud
AK, Pereyra M, Scalia IG, Kamel MA, Barry T, Lester SJ, Cannan CR,
et al: Role of genetics in diagnosis and management of hypertrophic
cardiomyopathy: A glimpse into the future. Biomedicines.
12(682)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang Z, Xia Q, Su W, Cao M, Sun Y, Zhang
M, Chen W and Jiang T: Exploring the communal pathogenesis,
ferroptosis mechanism, and potential therapeutic targets of dilated
cardiomyopathy and hypertrophic cardiomyopathy via a microarray
data analysis. Front Cardiovasc Med. 9(824756)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chase Cole J, Benvie SF and DeLosSantos M:
Mavacamten: A novel agent for hypertrophic cardiomyopathy. Clin
Ther. 46:368–373. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zampieri M, Argirò A, Marchi A, Berteotti
M, Targetti M, Fornaro A, Tomberli A, Stefàno P, Marchionni N and
Olivotto I: Mavacamten, a novel therapeutic strategy for
obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep.
23(79)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ottaviani A, Mansour D, Molinari LV,
Galanti K, Mantini C, Khanji MY, Chahal AA, Zimarino M, Renda G,
Sciarra L, et al: Revisiting diagnosis and treatment of
hypertrophic cardiomyopathy: Current practice and novel
perspectives. J Clin Med. 12(5710)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bakalakos A, Monda E and Elliott PM: The
diagnostic and therapeutic implications of phenocopies and mimics
of hypertrophic cardiomyopathy. Can J Cardiol. 40:754–765.
2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Pu L, Li J, Qi W, Zhang J, Chen H, Tang Z,
Han Y, Wang J and Chen Y: Current perspectives of sudden cardiac
death management in hypertrophic cardiomyopathy. Heart Fail Rev.
29:395–404. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Faisaluddin M, Balasubramanian S, Ahmed A,
Hussain K, Nso N, Gaznabi S, Erwin JP III, Pursnani A and Ricciardi
M: Temporal trends and procedural safety of transcatheter mitral
valve repair with mitraclip in patients with hypertrophic
cardiomyopathy: Insights from the national inpatient sample. Curr
Probl Cardiol. 49(102354)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yacoub MS, El-Nakhal T, Hasabo EA, Shehata
N, Wilson K, Ismail KH, Bakr MS, Mohsen M, Mohamed A, Abdelazim E,
et al: A systematic review and meta-analysis of the efficacy and
safety of Mavacamten therapy in international cohort of 524
patients with hypertrophic cardiomyopathy. Heart Fail Rev.
29:479–496. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen X, Tsvetkov AS, Shen HM, Isidoro C,
Ktistakis NT, Linkermann A, Koopman WJH, Simon HU, Galluzzi L, Luo
S, et al: International consensus guidelines for the definition,
detection, and interpretation of autophagy-dependent ferroptosis.
Autophagy. 24:1213–1246. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kaplan JL, Rivas VN and Connolly DJ:
Advancing treatments for feline hypertrophic cardiomyopathy: The
role of animal models and targeted therapeutics. Vet Clin North Am
Small Anim Pract. 53:1293–1308. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rivas VN, Kaplan JL, Kennedy SA,
Fitzgerald S, Crofton AE, Farrell A, Grubb L, Jauregui CE,
Grigorean G, Choi E, et al: Multi-omic, histopathologic, and
clinicopathologic effects of once-weekly oral rapamycin in a
naturally occurring feline model of hypertrophic cardiomyopathy: A
pilot study. Animals (Basel). 13(3184)2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dang JY, Zhang W, Chu Y, Chen JH, Ji ZL
and Feng P: Downregulation of salusins alleviates hypertrophic
cardiomyopathy via attenuating oxidative stress and autophagy. Eur
J Med Res. 29(109)2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Huang X, Zhang J, Wang W, Huang Z and Han
P: Vps4a regulates autophagic flux to prevent hypertrophic
cardiomyopathy. Int J Mol Sci. 24(10800)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rabinovich-Nikitin I and Kirshenbaum LA:
YAP/TFEB pathway promotes autophagic cell death and hypertrophic
cardiomyopathy in lysosomal storage diseases. J Clin Invest.
131(e146821)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang Y, Zhao J, Jin Q and Zhuang L:
Transcriptomic analyses and experimental validation identified
immune-related lncRNA-mRNA Pair MIR210HG-BPIFC regulating the
progression of hypertrophic cardiomyopathy. Int J Mol Sci.
25(2816)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43(e47)2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
R Core Team: A Language and Environment
for Statistical Computing. R Foundation for Statistical Computing,
Vienna, 2020. Available from: https://www.R-project.org/.
|
|
20
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4)(S11)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z,
Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A
universal enrichment tool for interpreting omics data. Innovation
(Camb). 2(100141)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gong J, Shi B, Yang P, Khan A, Xiong T and
Li Z: Unveiling immune infiltration characterizing genes in
hypertrophic cardiomyopathy through transcriptomics and
bioinformatics. J Inflamm Res. 17:3079–3092. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li N, Wang W, Zhou H, Wu Q, Duan M, Liu C,
Wu H, Deng W, Shen D and Tang Q: Ferritinophagy-mediated
ferroptosis is involved in sepsis-induced cardiac injury. Free
Radic Biol Med. 160:303–318. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expres-sion data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gao XM, Wong G, Wang B, Kiriazis H, Moore
XL, Su YD, Dart A and Du XJ: Inhibition of mTOR reduces chronic
pressure-overload cardiac hypertrophy and fibrosis. J Hypertens.
24:1663–1670. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Völkers M, Konstandin MH, Doroudgar S,
Toko H, Quijada P, Din S, Joyo A, Ornelas L, Samse K, Thuerauf DJ,
et al: Mechanistic target of rapamycin complex 2 protects the heart
from ischemic damage. Circulation. 128:2132–2144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pei HF, Hou JN, Wei FP, Xue Q, Zhang F,
Peng CF, Yang Y, Tian Y, Feng J, Du J, et al: Melatonin attenuates
postmyocardial infarction injury via increasing Tom70 expression. J
Pineal Res. 62:2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Reiter RJ, Mayo JC, Tan DX, Sainz RM,
Alatorre-Jimenez M and Qin L: Melatonin as an antioxidant: Under
promises but over delivers. J Pineal Res. 61:253–278.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dai H, Liu Y, Zhu M, Tao S, Hu C, Luo P,
Jiang A and Zhang G: Machine learning and experimental validation
of novel biomarkers for hypertrophic cardiomyopathy and cancers. J
Cell Mol Med. 28(e70034)2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Abbasi M, Ong KC, Newman DB, Dearani JA,
Schaff HV and Geske JB: Obstruction in hypertrophic cardiomyopathy:
Many faces. J Am Soc Echocardiogr. 37:613–625. 2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
McKinney J, Isserow M, Wong J, Isserow S
and Moulson N: New insights and recommendations for athletes with
hypertrophic cardiomyopathy. Can J Cardiol. 40:921–933.
2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Schaff HV and Wei X: Contemporary surgical
management of hypertrophic cardiomyopathy. Ann Thorac Surg.
117:271–281. 2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Maron BJ, Rowin EJ and Maron MS: Global
burden of hypertrophic cardiomyopathy. JACC Heart Fail. 6:376–378.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ding X, Zhu C, Wang W, Li M, Ma C and Gao
B: SIRT1 is a regulator of autophagy: Implications for the
progression and treatment of myocardial ischemia-reperfusion.
Pharmacol Res. 199(106957)2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rabinovich-Nikitin I, Kirshenbaum E and
Kirshenbaum LA: Autophagy, clock genes, and cardiovascular disease.
Can J Cardiol. 39:1772–1780. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhao J, Liu GW and Tao C: Hotspots and
future trends of autophagy in traditional chinese medicine: A
bibliometric analysis. Heliyon. 9(e20142)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sazonova EV, Petrichuk SV, Kopeina GS and
Zhivotovsky B: A link between mitotic defects and mitotic
catastrophe: Detection and cell fate. Biol Direct.
16(25)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Byrnes K, Blessinger S, Bailey NT, Scaife
R, Liu G and Khambu B: Therapeutic regulation of autophagy in
hepatic metabolism. Acta Pharm Sin B. 12:33–49. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Xiong R, Li N, Chen L, Wang W, Wang B,
Jiang W and Geng Q: STING protects against cardiac dysfunction and
remodelling by blocking autophagy. Cell Commun Signal.
19(109)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ikeda S, Zablocki D and Sadoshima J: The
role of autophagy in death of cardiomyocytes. J Mol Cell Cardiol.
165:1–8. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen B, Yang Y, Wu J, Song J and Lu J:
microRNA-17-5p downregulation inhibits autophagy and myocardial
remodelling after myocardial infarction by targeting STAT3.
Autoimmunity. 55:43–51. 2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhu QH, Zhou YL, Yang M, Yang BB, Cao WT,
Yuan LM and Deng DQ: Reduced miR-99a-3p levels in systemic lupus
erythematosus may promote B cell proliferation via NCAPG and the
PI3K/AKT signaling pathway. Lupus. 33:365–374. 2024.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Voeltzke K, Scharov K, Funk CM, Kahler A,
Picard D, Hauffe L, Orth MF, Remke M, Esposito I, Kirchner T, et
al: EIF4EBP1 is transcriptionally upregulated by MYCN and
associates with poor prognosis in neuroblastoma. Cell Death Discov.
8(157)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wu ZR, Yan L, Liu YT, Cao L, Guo YH, Zhang
Y, Yao H, Cai L, Shang HB, Rui WW, et al: Inhibition of mTORC1 by
lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary
tumours. Nat Commun. 9(4624)2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Nelson ED, Benesch MG, Wu R, Ishikawa T
and Takabe K: High EIF4EBP1 expression reflects mTOR pathway
activity and cancer cell proliferation and is a biomarker for poor
breast cancer prognosis. Am J Cancer Res. 14:227–242.
2024.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Montalban-Bravo G, Thongon N,
Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V,
Wildeman B, Tanaka T, et al: Targeting MCL1-driven anti-apoptotic
pathways overcomes blast progression after hypomethylating agent
failure in chronic myelomonocytic leukemia. Cell Rep Med.
5(101585)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mukherjee N, Katsnelson E, Brunetti TM,
Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris
DA, Tobin RP and Shellman YG: MCL1 inhibition targets myeloid
derived suppressors cells, promotes antitumor immunity and enhances
the efficacy of immune checkpoint blockade. Cell Death Dis.
15(198)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Clerbaux LA, Cordier P, Desboeufs N, Unger
K, Leary P, Semere G, Boege Y, Chan LK, Desdouets C, Lopes M and
Weber A: Mcl-1 deficiency in murine livers leads to nuclear
polyploidisation and mitotic errors: Implications for
hepatocellular carcinoma. JHEP Rep. 5(100838)2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chiou JT and Chang LS: Synergistic
cytotoxicity of decitabine and YM155 in leukemia cells through
upregulation of SLC35F2 and suppression of MCL1 and survivin
expression. Apoptosis. 29:503–520. 2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Boët E and Sarry JE: Targeting metabolic
dependencies fueling the TCA cycle to circumvent therapy resistance
in acute myeloid leukemia. Cancer Res. 84:950–952. 2024.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mukherjee N, Schwan JV, Fujita M, Norris
DA and Shellman YG: Alternative treatments for melanoma: Targeting
BCL-2 family members to de-bulk and kill cancer stem cells. J
Invest Dermatol. 135:2155–2161. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Kapoor I, Bodo J, Hill BT, Hsi ED and
Almasan A: Targeting BCL-2 in B-cell malignancies and overcoming
therapeutic resistance. Cell Death Dis. 11(941)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Neophytou CM, Trougakos IP, Erin N and
Papageorgis P: Apoptosis deregulation and the development of cancer
multi-drug resistance. Cancers (Basel). 13(4363)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Zhan H, Huang F, Niu Q, Jiao M, Han X,
Zhang K, Ma W, Mi S, Guo S and Zhao Z: Downregulation of miR-128
ameliorates Ang II-induced cardiac remodeling via SIRT1/PIK3R1
multiple targets. Oxid Med Cell Longev.
2021(8889195)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Dsouza NR, Cottrell CE, Davies OMT,
Tollefson MM, Frieden IJ, Basel D, Urrutia R, Drolet BA and
Zimmermann MT: Structural and dynamic analyses of pathogenic
variants in PIK3R1 reveal a shared mechanism associated among
cancer, undergrowth, and overgrowth syndromes. Life (Basel).
14(297)2024.PubMed/NCBI View Article : Google Scholar
|
|
57
|
De Bortoli M, Queisser A, Pham VC,
Dompmartin A, Helaers R, Boutry S, Claus C, De Roo AK, Hammer F,
Brouillard P, et al: Somatic loss-of-function PIK3R1 and activating
non-hotspot PIK3CA mutations associated with capillary malformation
with dilated veins (CMDV). J Invest Dermatol. 144:2066–2077.
2024.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Yu X, Xu C, Zou Y, Liu W, Xie Y and Wu C:
A prognostic metabolism-related gene signature associated with the
tumor immune microenvironment in neuroblastoma. Am J Cancer Res.
14:253–273. 2024.PubMed/NCBI View Article : Google Scholar
|
|
59
|
He B, Quan L, Li C, Yan W, Zhang Z, Zhou
L, Wei Q, Li Z, Mo J, Zhang Z, et al: Targeting ERBB2 and PIK3R1 as
a therapeutic strategy for dilated cardiomyopathy: A single-cell
sequencing and mendelian randomization analysis. Heliyon.
10(e25572)2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Maura F and Bergsagel PL: Molecular
pathogenesis of multiple myeloma: Clinical implications. Hematol
Oncol Clin North Am. 38:267–279. 2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Liu Z, Wang K, Jiang C, Chen Y, Liu F, Xie
M, Yim WY, Yao D, Qian X, Chen S, et al: Morusin alleviates aortic
valve calcification by inhibiting valve interstitial cell
senescence through Ccnd1/Trim25/Nrf2 axis. Adv Sci (Weinh).
19(e2307319)2024.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Zhang W and Hong W: Upregulation of
miR-519d-3p inhibits viability, proliferation, and G1/S cell cycle
transition of oral squamous cell carcinoma cells through targeting
CCND1. Cancer Biother Radiopharm. 39:153–163. 2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Quesada AE, Hu S, Li S, Toruner GA, Wei Q,
Loghavi S, Ok CY, Jain P, Thakral B, Nwogbo OV, et al: Optical
genomic mapping is a helpful tool for detecting CCND1
rearrangements in CD5-negative small B-cell lymphoma: Two cases of
leukemic non-nodal mantle cell lymphoma. Hum Pathol. 144:71–76.
2024.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Han B, Chen J, Chen S, Shen X, Hou L, Fang
J and Lian M: PPARG and the PTEN-PI3K/AKT signaling axis may
cofunction in promoting chemosensitivity in hypopharyngeal squamous
cell carcinoma. PPAR Res. 2024(2271214)2024.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Qin Y, Ashrafizadeh M, Mongiardini V,
Grimaldi B, Crea F, Rietdorf K, Győrffy B, Klionsky DJ, Ren J,
Zhang W and Zhang X: Autophagy and cancer drug resistance in
dialogue: Pre-clinical and clinical evidence. Cancer Lett.
570(216307)2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Jia Q, Li B, Wang X, Ma Y and Li G:
Comprehensive analysis of peroxisome proliferator-activated
receptors to predict the drug resistance, immune microenvironment,
and prognosis in stomach adenocarcinomas. PeerJ.
12(e17082)2024.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Sun Y, Ma J, Lin J, Sun D, Song P, Shi L,
Li H, Wang R, Wang Z and Liu S: Circular RNA circ_ASAP2 regulates
drug sensitivity and functional behaviors of cisplatin-resistant
gastric cancer cells by the miR-330-3p/NT5E axis. Anticancer Drugs.
32:950–961. 2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Choi JC, Muchir A, Wu W, Iwata S, Homma S,
Morrow JP and Worman HJ: Temsirolimus activates autophagy and
ameliorates cardiomyopathy caused by lamin A/C gene mutation. Sci
Transl Med. 4(144ra102)2012.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Gan T, Qu S, Zhang H and Zhou XJ:
Modulation of the immunity and inflammation by autophagy. MedComm
(2020). 4(e311)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Herb M, Gluschko A and Schramm M:
LC3-associated phagocytosis-the highway to hell for phagocytosed
microbes. Semin Cell Dev Biol. 101:68–76. 2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Castillo EF, Dekonenko A, Arko-Mensah J,
Mandell MA, Dupont N, Jiang S, Delgado-Vargas M, Timmins GS,
Bhattacharya D, Yang H, et al: Autophagy protects against active
tuberculosis by suppressing bacterial burden and inflammation. Proc
Natl Acad Sci USA. 109:E3168–E3176. 2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Ma CS: Human T follicular helper cells in
primary immunodeficiency: Quality just as important as quantity. J
Clin Immunol. 36 (Suppl 1):S40–S47. 2016.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Singh SR, Zech ATL, Geertz B,
Reischmann-Düsener S, Osinska H, Prondzynski M, Krämer E, Meng Q,
Redwood C, van der Velden J, et al: Activation of autophagy
ameliorates cardiomyopathy in mybpc3-targeted knockin mice. Circ
Heart Fail. 10(e004140)2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Hassoun R, Budde H, Zhazykbayeva S, Herwig
M, Sieme M, Delalat S, Mostafi N, Gömöri K, Tangos M, Jarkas M, et
al: Stress activated signalling impaired protein quality control
pathways in human hypertrophic cardiomyopathy. Int J Cardiol.
344:160–169. 2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Simpson JE and Gammoh N: Autophagy
cooperates with PDGFRA to support oncogenic growth signaling.
Autophagy. 20:1901–1902. 2024.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Ravikumar B, Sarkar S, Davies JE, Futter
M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M,
Korolchuk VI, Lichtenberg M, Luo S, et al: Regulation of Mammalian
autophagy in physiology and pathophysiology. Physiol Rev.
90:1383–1435. 2010.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Marian AJ and Braunwald E: Hypertrophic
cardiomyopathy: Genetics, pathogenesis, clinical manifestations,
diagnosis, and therapy. Circ Res. 121:749–770. 2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Tannous P, Zhu H, Johnstone JL, Shelton
JM, Rajasekaran NS, Benjamin IJ, Nguyen L, Gerard RD, Levine B,
Rothermel BA and Hill JA: Autophagy is an adaptive response in
desmin-related cardiomyopathy. Proc Natl Acad Sci USA.
105:9745–9750. 2008.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Sheng SY, Li JM, Hu XY and Wang Y:
Regulated cell death pathways in cardiomyopathy. Acta Pharmacol
Sin. 44:1521–1535. 2023.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Buss SJ, Muenz S, Riffel JH, Malekar P,
Hagenmueller M, Weiss CS, Bea F, Bekeredjian R, Schinke-Braun M,
Izumo S, et al: Beneficial effects of Mammalian target of rapamycin
inhibition on left ventricular remodeling after myocardial
infarction. J Am Coll Cardiol. 54:2435–2446. 2009.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Sciarretta S, Volpe M and Sadoshima J:
Mammalian target of rapamycin signaling in cardiac physiology and
disease. Circ Res. 114:549–564. 2014.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Marin TM, Keith K, Davies B, Conner DA,
Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, et al:
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of
LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest.
121:1026–1043. 2011.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Sciarretta S, Forte M, Frati G and
Sadoshima J: New insights into the role of mTOR signaling in the
cardiovascular system. Circ Res. 122:489–505. 2018.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Yang Y, Du J, Xu R, Shen Y, Yang D, Li D,
Hu H, Pei H and Yang Y: Melatonin alleviates angiotensin-II-induced
cardiac hypertrophy via activating MICU1 pathway. Aging (Albany
NY). 13:493–515. 2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Chen S, Sun P, Li Y, Shen W, Wang C, Zhao
P, Cui H, Xue JY and Du GQ: Melatonin activates the Mst1-Nrf2
signaling to alleviate cardiac hypertrophy in pulmonary arterial
hypertension. Eur J Pharmacol. 933(175262)2022.PubMed/NCBI View Article : Google Scholar
|
